<DOC>
	<DOCNO>NCT00195104</DOCNO>
	<brief_summary>The purpose study find effectiveness side effect arsenic trioxide combination low-dose ara-C .</brief_summary>
	<brief_title>Arsenic Trioxide Combination With Cytarabine Patients With High-risk MDS Poor-prognosis AML</brief_title>
	<detailed_description>This open-label , single institution , dose-escalation study low-dose cytosine arabinoside arsenic trioxide . Patients receive fix dose arsenic trioxide administer 0.25mg/kg/day day 1-5 8-12 ara-C administer 5 , 7.5 , 10 mg/m2 SC BID day 1-14 repeat cycle 2 week therapy 2 week therapy standard dose escalation design ( 1 cycle = 2 week therapy + 2 week therapy ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Histologic diagnosis highrisk MDS ( IPSS int2 ) . No prior cytotoxic therapy MDS AML ( patient may receive prior therapy hematopoietic growth factor , immunomodulatory agent 5azacitidine ) . Pregnant lactating woman . Absolute QT interval &gt; 460 msec presence serum potassium magnesium value within normal range . Concurrent treatment maintenance therapy , cytotoxic chemotherapy , radiation , investigational agent . Uncontrolled severe cardiovascular pulmonary disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
</DOC>